ArticleISRN neurology2013
Intrathecal Administration of Autologous CD34 Positive Cells in Patients with Past Cerebral Infarction: A Safety Study.
Article in ISRN neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Stem cell transplantation for ischemic stroke.The Cochrane database of systematic reviews · 2019Pooled it
- A Randomized, Placebo-Controlled, Phase II Trial of Intravenous Allogeneic Non-HLA Matched, Unrelated Donor, Cord Blood Infusion for Ischemic Stroke.Stem cells translational medicine · 2024Trial
- Progress in Intra-Arterial Stem Cell Therapy for Ischemic Stroke: A Review.Stroke (Hoboken, N.J.) · 2026Review
- "Time Is Brain" - for Cell Therapies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Clinical trials and advanced MRI techniques with stem cell therapy for ischemic stroke: present and future perspectives.Journal of translational medicine · 2025Review
- Angiogenic Cell Precursors and Neural Cell Precursors in Service to the Brain-Computer Interface.Cells · 2025Review
- Overview of Cellular Therapeutics Clinical Trials: Advances, Challenges, and Future Directions.International journal of molecular sciences · 2025Review
- Review
- Editing a gateway for cell therapy across the blood-brain barrier.Brain : a journal of neurology · 2023Review
- Potential Mechanisms and Perspectives in Ischemic Stroke Treatment Using Stem Cell Therapies.Frontiers in cell and developmental biology · 2021Review
- Clinical Trials of Stem Cell Therapy for Cerebral Ischemic Stroke.International journal of molecular sciences · 2020Review
- Promoting Brain Repair and Regeneration After Stroke: a Plea for Cell-Based Therapies.Current neurology and neuroscience reports · 2019Review
- The spleen may be an important target of stem cell therapy for stroke.Journal of neuroinflammation · 2019Review
- The Dark Side of the Force - Constraints and Complications of Cell Therapies for Stroke.Frontiers in neurology · 2015Review
- Efficacy and safety of stem cell therapies for patients with stroke: a systematic review and single arm meta-analysis.International journal of stem cells · 2014Review
- Diffuse axonal injury after traumatic cerebral microbleeds: an evaluation of imaging techniques.Neural regeneration research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regenerative strategies in treatment of stroke have great potential. The goal of the current study was to investigate safety of intrathecal administration of autologous CD34 positive cells in treatment of patients with poststroke. A total of eight male patients with a history of stroke were enrolled. The patients were treated subcutaneously with 5 μ g/kg body weight rhG-CSF for 5 consecutive days, and then leukapheresis was performed to concentrate cells for CD34 positive immunoselection. All patients underwent intrathecal administration of CD34 positive cells via lumbar puncture. The primary outcome was safety evaluation for 12-month followup. In addition, behavioral function was evaluated with NIH stroke scale and Barthel index 1, 6, and 12 months after the last treatment, respectively. There were no major adverse events, and abnormal changes of blood tests during the whole treatment process included intrathecal administration and 12-month followup. The main message from the current study was that administration of G-CSF-mobilized autologous CD34 positive cells in patients with poststroke was safe. Future studies with larger population and control group are needed to confirm the safety and investigate the efficacy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.